The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
New research suggests that GLP-1 agonists, like semaglutide, may reduce alcohol cravings and delay intoxication. The effect is linked to slowed gastric emptying, impacting alcohol absorption. Track your peptide journey and wellness goals using Shotlee.
New research reveals that GLP-1 weight loss injections, such as semaglutide, may offer significant heart health benefits independent of weight loss. This could change how we view and use these medications for long-term health.
Recent approval of Mounjaro (tirzepatide) for obstructive sleep apnea (OSA) in obese individuals signifies a groundbreaking advancement. This development addresses a critical need, offering a novel pharmacological approach to a condition affecting millions.
Obstructive sleep apnea (OSA) affects millions, disrupting sleep and impacting overall health. A recent study explores the effectiveness of hypoglossal nerve stimulation as a promising treatment option for those who haven't found relief with traditional methods.
Tuberculosis remains a global health challenge. Recent research explores the potential of cytochrome bc1 inhibitors in novel treatment regimens, offering a glimpse into future TB therapies. Learn about this promising development.
Struggling to find time or money for fitness? Your smartphone might be the solution. Discover how to leverage built-in features and apps for a healthier lifestyle, no gym required.
Recent news highlights the importance of safe pharmacy practices in the production of GLP-1 weight loss drugs. Understand the regulations, potential risks, and how to ensure you're getting safe and effective medication.
Employers are grappling with the rising costs of GLP-1 agonists like Ozempic and Wegovy for weight loss. A new KFF analysis reveals potential shifts in coverage as companies weigh the benefits against financial burdens. Discover strategies for navigating this evolving landscape and prioritizing metabolic health.
Recent leadership changes at Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy, have sparked discussions about the future of GLP-1 innovation and the company's direction. What does this mean for the future of weight loss drugs and metabolic health?
